TCGA-55-8096-01A-11R-2241-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 67
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- ANGIOGENESIS+0.440
- COAGULATION+0.370
- MYOGENESIS+0.340
- KRAS_SIGNALING_UP+0.320
- PANCREAS_BETA_CELLS+0.290
- KRAS_SIGNALING_DN+0.190
- COMPLEMENT+0.180
- INFLAMMATORY_RESPONSE+0.180
- HEDGEHOG_SIGNALING+0.170
Top 10 suppressed
- E2F_TARGETS-0.680
- MYC_TARGETS_V1-0.630
- G2M_CHECKPOINT-0.600
- MYC_TARGETS_V2-0.580
- OXIDATIVE_PHOSPHORYLATION-0.490
- UNFOLDED_PROTEIN_RESPONSE-0.450
- DNA_REPAIR-0.440
- INTERFERON_ALPHA_RESPONSE-0.410
- MTORC1_SIGNALING-0.370
- PI3K_AKT_MTOR_SIGNALING-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR15069598 | — | — | 0.907 |
| 2 | TCGA-BB-8596-01A-11R-2403-07 | — | — | 0.897 |
| 3 | SRR8518451 | — | A | 0.895 |
| 4 | TCGA-97-8547-01A-11R-2403-07 | — | cohortA1 | 0.889 |
| 5 | DRR168582 | — | — | 0.889 |
| 6 | TCGA-ZF-A9R9-01A-11R-A38B-07 | — | — | 0.887 |
| 7 | SRR8942991 | — | — | 0.884 |
| 8 | TCGA-G2-A2EC-01A-11R-A180-07 | — | — | 0.884 |
| 9 | TCGA-49-4512-01A-21R-1858-07 | — | cohortA1 | 0.883 |
| 10 | SRR12202400 | — | — | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.170 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.070 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.050 | Inavolisib | — uncovered |
| HYPOXIA | 0.040 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.030 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.010 | Inavolisib | — uncovered |